Webinar & Summary

An increasing number of advanced therapies and orphan drugs, targeting small patient populations, face challenges when aligning with the traditional drug development pathway. It means walking the tightrope between having early access to new medicines for patients who urgently need it while maintaining the rigorous control of safety and efficacy of the product throughout the approval process.

In this webinar our NDA Advisory Board Member, Jan Sjöberg (former IWA, SAWP and CHMP member),  discusses the regulatory perspective of unmet medical need as a key criterion for drug development, based on his experience as an former EU regulator.


Dr Jan Sjöberg

Medical Advisor and NDA Advisory Board Member


You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.